Programmed death-1 inhibitors as treatment for other subtypes of lymphomas not recommended in the guidelines: Real-world data from a single center in China

Abstract

Abstract In recent years, PD-1 inhibitors have shined in some subtypes of lymphoma, including Classic Hodgkin’s lymphoma, Primary Mediastinal Large B-cell Lymphoma, and Natural Killer/T-cell Lymphoma, recommended by clinical practice guidelines. It is unknown how effective are PD-1 inhibitors used for other subtypes not recommended by the guidelines. We conducted a retrospective study in a real-world setting to evaluate efficacy of PD-1 inhibitors for other subtypes not recommended by the guidelines and discuss the potential biomarkers of treatment outcome. We found that the efficacy in some subtypes seems all right, especially in PCNSL. And the kinetics of Neutrophil to Lymphocyte Ratio and Lactate dehydrogenase may indicate clinical outcomes. Thus, PD-1 inhibitor is a promising choice for lymphoma patients. Further screening and monitoring of patients may bring more clinical benefits.